Celldex Therapeutics, Inc. (CLDX)
NASDAQ: CLDX · IEX Real-Time Price · USD
34.67
-1.76 (-4.83%)
Jun 14, 2024, 4:00 PM EDT - Market closed

Celldex Therapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Year Current20232022202120202019 2018 - 1996
Market Capitalization
2,2851,8742,0991,80369336
Upgrade
Market Cap Growth
--10.71%16.42%160.11%1827.20%5.39%
Upgrade
Enterprise Value
1,4631,4531,7981,398502-25
Upgrade
PE Ratio
-16.19-13.25-18.69-25.57-11.60-0.71
Upgrade
PS Ratio
376.34272.34890.64387.6893.4510.07
Upgrade
PB Ratio
2.724.376.444.303.310.38
Upgrade
P/FCF Ratio
-19.40-17.18-19.90-29.02-16.54-0.76
Upgrade
P/OCF Ratio
-19.66-17.47-20.24-29.60-17.16-0.77
Upgrade
EV/Sales Ratio
241.01211.16762.97300.5667.71-6.93
Upgrade
EV/EBITDA Ratio
-10.75-10.50-16.43-20.66-8.810.54
Upgrade
EV/EBIT Ratio
-10.52-10.28-16.01-19.76-8.240.49
Upgrade
EV/FCF Ratio
-12.61-13.32-17.05-22.50-11.990.53
Upgrade
Debt / Equity Ratio
0.000.010.010.010.020.04
Upgrade
Debt / EBITDA Ratio
-0.01-0.02-0.04-0.04-0.06-0.08
Upgrade
Debt / FCF Ratio
-0.02-0.02-0.04-0.05-0.08-0.08
Upgrade
Quick Ratio
31.4413.6916.4124.7113.815.62
Upgrade
Current Ratio
31.7713.8717.0724.8613.935.73
Upgrade
Asset Turnover
0.010.020.010.010.030.03
Upgrade
Return on Equity (ROE)
-32.30%-45.00%-31.30%-22.90%-31.40%-48.70%
Upgrade
Return on Assets (ROA)
-30.30%-41.30%-29.00%-21.20%-27.60%-37.40%
Upgrade
Return on Capital (ROIC)
-19.35%-35.80%-36.97%-17.19%-31.75%-57.66%
Upgrade
Earnings Yield
-6.34%-7.54%-5.35%-3.91%-8.62%-141.45%
Upgrade
FCF Yield
-5.29%-5.82%-5.03%-3.45%-6.04%-131.01%
Upgrade
Buyback Yield / Dilution
-24.69%-3.33%-9.37%-44.64%-104.32%-38.93%
Upgrade
Total Shareholder Return
-24.69%-3.33%-9.37%-44.64%-104.32%-38.93%
Upgrade
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).